- Home
- RFI vs ALDX Comparison
RFI vs ALDX Comparison
Compare RFI & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- ALDX
- Stock Information
- Founded
- RFI 1992
- ALDX 2004
- Country
- RFI United States
- ALDX United States
- Employees
- RFI N/A
- ALDX N/A
- Industry
- RFI Investment Managers
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- RFI Finance
- ALDX Health Care
- Exchange
- RFI Nasdaq
- ALDX Nasdaq
- Market Cap
- RFI 321.0M
- ALDX 304.9M
- IPO Year
- RFI N/A
- ALDX 2014
- Fundamental
- Price
- RFI $11.92
- ALDX $6.62
- Analyst Decision
- RFI
- ALDX Strong Buy
- Analyst Count
- RFI 0
- ALDX 2
- Target Price
- RFI N/A
- ALDX $10.00
- AVG Volume (30 Days)
- RFI 69.8K
- ALDX 636.8K
- Earning Date
- RFI 01-01-0001
- ALDX 05-01-2025
- Dividend Yield
- RFI 8.25%
- ALDX N/A
- EPS Growth
- RFI N/A
- ALDX N/A
- EPS
- RFI N/A
- ALDX N/A
- Revenue
- RFI N/A
- ALDX N/A
- Revenue This Year
- RFI N/A
- ALDX N/A
- Revenue Next Year
- RFI N/A
- ALDX N/A
- P/E Ratio
- RFI N/A
- ALDX N/A
- Revenue Growth
- RFI N/A
- ALDX N/A
- 52 Week Low
- RFI $9.62
- ALDX $2.71
- 52 Week High
- RFI $12.52
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- RFI 39.29
- ALDX 62.09
- Support Level
- RFI $11.61
- ALDX $6.79
- Resistance Level
- RFI $12.52
- ALDX $7.20
- Average True Range (ATR)
- RFI 0.19
- ALDX 0.55
- MACD
- RFI -0.07
- ALDX 0.03
- Stochastic Oscillator
- RFI 19.78
- ALDX 88.84
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.